CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 60 enrolled
Drug / intervention
Dexmedetomidine / Ketamine / Lidocainedrug
Likely dose
Dexmedetomidine / Ketamine / Lidocaine 5 mcg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04724759
NCT04724759Phase 2Completed
CompareCT.gov

The Effect of Opioid-Free Anesthesia in TMJ Surgery: A Prospective Study

Massachusetts General Hospital·interventional·Posted Jan 26, 2021·Updated Nov 21, 2024

In Brief

A Phase 2 clinical trial evaluating Dexmedetomidine / Ketamine / Lidocaine for Temporomandibular Joint Disorders. Completed, enrolled 60 participants across 1 site.

Detailed Summary

This study aims is to evaluate the effect of opioid free total intravenous anesthesia on postoperative quality of recovery in patients undergoing oral and maxillofacial surgery (OMF) temporomandibular joint (TMJ) surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTemporomandibular Joint Disorders
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedJan 26, 2021
Enrollment StartJun 18, 2021
Primary CompletionApr 23, 2023
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 5.4 years ago

Interventions

Dexmedetomidine / Ketamine / Lidocainedrug

Patients in this group will receive an infusion of lidocaine, ketamine, or dexmedetomidine supplemented with other intravenous analgesics and intravenous and inhaled anesthetics, as needed clinically. This includes administration of 5 mcg/kg/min of ketamine plus 0.5 - 1.0 µg/kg/hr of dexmedetomidine (Precedex) as a continuous infusion, started from induction to stop one hour before surgery is anticipated to end.